Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Macitentan on Rosuvastatin PK in Healthy Males
NCT03359291Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Area Under the Curve from Time Zero to Infinity and Maximum Plasma Concentration. Started Nov 2017; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03359291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359291.